LifeSci Capital Starts Neurogene (NGNE) at Outperform Jan 26, 2026 07:50AM
Stifel on Neurogene (NGNE): 'We continue to think that NGNE has a viable safety margin with the low dose' Jan 12, 2026 07:57AM
Neurogene doses patients in registrational trial for Rett syndrome therapy Jan 12, 2026 07:00AM
Taysha's (TSHA) 'Moving into Registrational Studies, Shows Promise' - Citizens Dec 17, 2025 05:28AM
Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA) Nov 14, 2025 07:26AM


Nov 13, 2025 09:45AM Stifel Reiterates Buy Rating on Neurogene (NGNE)
Nov 13, 2025 06:44AM Neurogene (NGNE) PT Raised to $70 at H.C. Wainwright
Oct 9, 2025 07:01AM Neurogene completes FDA discussions for Rett syndrome gene therapy trial
Oct 3, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE)
Aug 14, 2025 08:01AM Stifel Reiterates Buy Rating on Neurogene (NGNE)
Aug 11, 2025 05:01PM Neurogene (NGNE) Misses Q2 EPS by 105c
Jul 1, 2025 08:21AM Stifel Reiterates Buy Rating on Neurogene (NGNE)
Jun 30, 2025 04:02PM Neurogene (NGNE) Announces Registrational Trial Design for Embolden Study of NGN-401 Gene Therapy
Jun 17, 2025 09:17AM Craig-Hallum Starts Neurogene (NGNE) at Buy
Jun 11, 2025 04:02PM Neurogene (NGNE) PT Raised to $26 at BMO Capital
Jun 5, 2025 12:44PM FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
May 29, 2025 08:58AM Stifel Reiterates Buy Rating on Neurogene (NGNE)
May 19, 2025 12:29PM Neurogene (NGNE) PT Raised to $22 at BMO Capital
May 16, 2025 07:01AM Neurogene (NGNE) Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
May 16, 2025 03:35AM Baird Downgrades Neurogene (NGNE) to Neutral
Apr 14, 2025 05:05AM Neurogene (NGNE) PT Lowered to $16 at BMO Capital
Apr 2, 2025 04:01PM Neurogene (NGNE) Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
Mar 26, 2025 07:05AM Stifel Reiterates Buy Rating on Neurogene (NGNE)
Mar 24, 2025 04:38PM Neurogene (NGNE) Files Mixed Shelf
Nov 25, 2024 06:47AM H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE)
Nov 20, 2024 04:54PM Neurogene (NGNE) PT Lowered to $46 at Stifel
Nov 19, 2024 04:02PM Neurogene (NGNE) PT Lowered to $45 at BMO Capital
Nov 19, 2024 11:07AM BMO Capital Reiterates Outperform Rating on Neurogene (NGNE)
Nov 19, 2024 03:50AM Neurogene (NGNE) Reports In-Line Q3 EPS
Nov 18, 2024 06:45AM Neurogene (NGNE) Provides Update on NGN-401 Gene Therapy Trial
Nov 12, 2024 09:09AM Neurogene (NGNE) PT Raised to $60 at Stifel
Nov 12, 2024 09:09AM Neurogene (NGNE) PT Lowered to $60 at BMO Capital
Nov 12, 2024 07:16AM Neurogene (NGNE) PT Raised to $72 at Baird
Nov 12, 2024 06:57AM Neurogene (NGNE) PT Raised to $55 at H.C. Wainwright
Nov 11, 2024 04:51PM After-hours movers: Live Nation Entertainment, Zeta Global, and more
Nov 11, 2024 04:01PM Neurogene (NGNE) Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Nov 4, 2024 07:32AM Neurogene (NGNE) Announces Oversubscribed $200 Million Private Placement
Oct 16, 2024 07:53AM BMO Capital Reiterates Outperform Rating on Neurogene (NGNE)
Aug 14, 2024 10:14AM BMO Capital Reiterates Outperform Rating on Neurogene (NGNE)
Aug 12, 2024 06:52AM Neurogene (NGNE) PT Lowered to $49 at H.C. Wainwright
Aug 7, 2024 07:30AM Neurogene (NGNE) Receives RMAT Designation for NGN-401
Jul 12, 2024 07:49AM BMO Capital Reiterates Outperform Rating on Neurogene (NGNE)
Jun 26, 2024 04:04PM BMO Capital Starts Neurogene (NGNE) at Outperform
Jun 11, 2024 05:04AM Baird Starts Neurogene (NGNE) at Outperform